Guided low, delivered loss. Recovery path unclear.

Cohance flagged Q1 FY27 as a trough — revenue down 23%, EBITDA minimal — and delivered exactly that. What management did not fully preview: profit would crater 197% and turn negative. The culprit is not revenue collapse, but NJ Bio consolidation. The acquired ADC payload subsidiary contributed ₹350 crore in revenue but -₹328 crore in EBITDA — a 94% negative margin that pulled the consolidated P&L underwater, even as the standalone business (₹3,599 crore revenue at 9.2% EBITDA margin) remained operationally sound.

Segment reality is split. Sapala (oligonucleotides) delivered ₹274 crore at 2.5x YoY growth with strong EBITDA margins — the only bright spot, with orphan drug program shipments live and amidites facility commercialization underway. Pharma CDMO (small molecule, ADC linkers, KSM) revenue fell 38.7% YoY, but this is shipment timing: 10 Phase 3 molecules are in the pipeline, with deliveries moving from Q1 into Q2/Q3. Specialty Chemicals declined 34.7% YoY, with AgChem weak but FY27 positioned as 'year of qualification' for new products. API+ held up (60% of standalone revenue), with favorable pricing and product mix offsetting formulation timing delays. But NJ Bio — the consolidation now mandatory rather than optional — remains the anchor on consolidated margin.

Three material shifts from prior guidance: (1) NJ Bio consolidation now mandatory. The acquisition integration pulled consolidated EBITDA margin down from 9.2% (standalone) to 2.2%. This was acknowledged but not flagged as a new or material surprise—signaling underestimated integration risk. (2) ₹1 billion FY30 revenue target downgraded to 'aspiration'. CEO Umang Vohra explicitly said the target 'may be a little bit away' over the next 3–4 years and deferred granularity to December. This is a meaningful credibility hit. (3) H2 FY27 recovery thesis reaffirmed but timeline vague. Phase 3 conversions (10 molecules, >50% approval hoped), restocking over 2 years, Sapala scaling—all material but unproven, with no quantified milestone or confidence interval.

The market believed the recovery narrative. The day-1 pop of +3.49% after the result announcement (Aug 5) held and strengthened: by day 3 it was +5.2%, and by day 5 it had settled at +4.59%, a managed hold. No fade suggests institutional conviction in the H2 thesis. However, context matters: the stock trades at ₹440.65, down 50.65% from its all-time high of ₹892.85, and sits above its 20-day SMA (₹435.68) but below its 200-day (₹448.29) — a position that signals near-term relief but longer-term weakness. FII ownership ticked up 0.91 percentage points to 6.50%, a modest add into weakness, while DII trimmed 1.7 points to 20.09%, suggesting domestic institutions are more cautious. Promoter ownership is stable at 57.49%. The divergence — FII nibbling, DII trimming — suggests the institutional view is split: foreigners see valuation opportunity in a CDMO turnaround, while domestic investors remain skeptical of execution.